Recent advances in targeted strategies for triple-negative breast cancer.

J Hematol Oncol · 2023 · PMC10464091 · PMID 37641116

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The GeparNUEVO trial used durvalumab in the neoadjuvant setting for TNBC and observed an increase in pCR, improvement in iDFS and DDFS, and a favorable trend in OS [ 210 , 211 ].

also in 377 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.